Amir Mortazavi, MD

Amir Mortazavi

College

College of Medicine

Division/Department

Internal Medicine

Academic Title

Asst Professor

Research Program

Molecular Carcinogenesis and Chemoprevention

Research Interest

Urinary Bladder Neoplasms, Urologic Neoplasms

Dr. Mortazavi's research interests include epigenetic modifications and experimental therapeutics for the prevention and treatment of genitourinary cancers.


Education and Background

Office Locations

A441 Starling Loving Hall

320 W 10th Avenue, Columbus, Ohio 43210


614-293-2886

614-293-7525



Publications


  • Cervical cancer and HPV: knowledge, attitudes, beliefs, and behaviors among women living in Guatemala.

    Petrocy A, Katz ML

    J Health Care Poor Underserved 25 624-36 05/01/2014


  • Cerebellar cortical lamination and foliation require cyclin A2.

    Otero JJ, Kalaszczynska I, Michowski W, Wong M, Gygli PE, Gokozan HN, Griveau A, Odajima J, Czeisler C, Catacutan FP, Murnen A, Schüller U, Sicinski P, Rowitch D

    Dev Biol 385 328-39 01/15/2014


  • A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

    Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O

    Eur J Cancer 49 2345-55 07/01/2013


  • Myelodysplastic syndromes: clinical practice guidelines in oncology.

    Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M, Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL

    J Natl Compr Canc Netw 11 838-74 07/01/2013


  • A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.

    Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B, SWE-BRCA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benítez J, Hamann U, HEBON, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Jager A, van der Luijt RB, EMBRACE, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H, GEMO Study Collaborators, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Léoné M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomäki K, Simard J, KConFab Investigators, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H, OCGN, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), DeMars LR, DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B

    Cancer Epidemiol Biomarkers Prev 21 1362-70 08/01/2012


  • Atypical E2F repressors and activators coordinate placental development.

    Ouseph MM, Li J, Chen HZ, Pécot T, Wenzel P, Thompson JC, Comstock G, Chokshi V, Byrne M, Forde B, Chong JL, Huang K, Machiraju R, de Bruin A, Leone G

    Dev Cell 22 849-62 04/17/2012


  • Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation.

    Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, Kurokawa M

    Eur J Immunol 42 1044-50 04/01/2012


  • MicroRNAs in the pathogenesis of cancer.

    Lovat F, Valeri N, Croce CM

    Semin Oncol 38 724-33 12/01/2011

  • See Full List
Back to Researcher Search